To assess the functionality of the identified IRF3/BCL2L12 promoter mutations, we evaluated their impact on IRF3 and BCL2L12 mRNA expression in melanoma tumor samples (Figure 2C). This evidence concerns the gene BCL2L12 and neoplasm.